A balanced business driven by focus and execution

41st Annual J.P. Morgan Healthcare Conference

Thierry Bernard
Chief Executive Officer



Disclaimer

Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including factors such as general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to “Risk Factors” section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law.

Our Mission

Enabling access to valuable insights from molecular research to clinical healthcare

Our Vision

Making improvements in life possible

Balance: Well-diversified business spanning attractive markets

Diversified customer base

Well-balanced leadership in Life Sciences and Molecular Diagnostics

Life Sciences

Molecular Diagnostics



Net sales (In $ billions at actual rates)

Broad geographic reach

>6,300 QIAGENers ensuring access to attractive markets with shipments to >170 countries



Highly recurring revenues

Growing installed base generating demand for high-margin consumables

~88%
Consumables and related revenues

~12%
Instruments

Focus: Leveraging a strong core portfolio to drive 5 Pillars of Growth

Expanding on solid leadership

Early commercialization phases with strong growth potential

5 Pillars of Growth

Sample technologies
Comprehensive portfolio

QuantiFERON
Leading immune response monitoring (incl. TB)

QIAstat-Dx
Syndromic testing with unrivaled ease of use

NeuMoDx
Differentiated microfluidic integrated PCR testing

QIAcuity
Novel microplate digital PCR

2021 sales

Sample technologies	Diagnostic solutions	PCR / Nucleic acid amplification	NGS / Genomics
$851 m	$639 m	$434 m	$245 m

Core portfolios

- Microbiome
- Liquid Biopsy
- HID / Forensics
- Immune response
- Infectious diseases
- Oncology / Precision Medicine
- OEM Reagents
- Universal NGS solutions
- QIAGEN Digital Insights

Execution: Delivering on our commitments

Commitments	Execution
✓ **Commercial execution**	• 12 consecutive quarters of meeting or beating guidance • 7 consecutive quarters of double-digit CER non-COVID sales growth
✓ **Innovation focus**	• >60% of R&D investments into 5 Pillars of Growth
✓ **Solid installed base growth(1)**	• QIAsymphony: ~3,200; QIAcube: >14,000; EZ1/EZ2: >5,000 • QIAstat-Dx: >3,500; NeuMoDx: ~300; QIAcuity: >1,300
✓ **Expanded test menu**	• QIAstat-Dx: 5 CE-IVD panels / 1 panel FDA approved + 1 pending • NeuMoDx: 16 CE-IVD tests / 3 FDA tests • QIAcuity: >15 new application kits
✓ **Increased production capacity**	• Sample technologies: +15% increase in capacity • QIAstat-Dx: New high-throughput automated cartridge capacity • NeuMoDx: 35% increase in consumables capacity
✓ **Strong free cash flow**	• $505 m in 9M 2022 vs. $135 m in 9M 2019
✓ **Growing diversity of teams**	• >6,300 QIAGENers worldwide • 34% Women in leadership in 2021
✓ **Enhanced governance**	• 3 new Supervisory Board members since 2021

Priorities

- Increase efficiency of regulatory processes
- Streamline execution of launch timelines
- Drive digitalization across QIAGEN
- Create greater value with targeted M&A

2019 2020 2021 2022 2023 and beyond

(1) Cumulative placements as of December 31, 2022

Execution: Advancing our 5 Pillars of Growth

2022 Achievements	2022 CER sales goal
Sample technologies • QIAwave consumables – new environmentally friendly portfolio • EZ2 Connect upgraded instrument launched • QIAxcel capillary electrophoresis launched	>$750 m
QuantiFERON • Milestone: >100 million patients tested for TB • Expanded patient groups: Weakened immune system, pregnant women, children • China approval for QFT-TB Gold (4th generation)	>$310 m
QIAstat-Dx • EU launch of QIAstat-Dx Rise high-throughput platform • CE-IVD Meningitis panel launched • New Viral Vesicular panel for monkeypox	>$85 m
NeuMoDx • 16th CE-IVD test: Herpes Simplex Virus 1/2 assay • New Viral Vesicular test for monkeypox • CE-IVDR platform certification	>$80 m
QIAcuity digital PCR • 13 biopharma kits launched for cell and gene therapy R&D • New partnerships for wastewater testing and proteomics • Development milestones towards IVD submission	>$55 m

CER – Constant exchange rates
IVDR – In vitro diagnostic recast (new European Union regulatory standards)

Execution: 2022 Full-year outlook

Outlook (As of November 7, 2022)

Net sales **~$2.25 bn CER**

Double-digit CER growth in non-COVID products

Adj. EPS **~$2.40 CER**

Effectively managing a dynamic macro environment

Outbreaks

- Launched >12 new COVID-19 and monkeypox tests since outbreak
- Increased production capacity for QIAstat-Dx, NeuMoDx and QIAcuity

Inflation

- Working with customers on price adjustments
- One-time payment to support employees

Energy

- Implemented new energy sources at Germany site
- No reliance on natural gas for production

Supply

- Secured secondary suppliers outside of Asia
- Utilized extended inventory/order periods

Sample Technologies: Continuing to build on strong leadership

Why we win

Comprehensive portfolio
>300 consumables kits and range of automation systems

Any sample type

- Stool
- Saliva
- Bone
- Plants
- Soil
- Tissue
- Cells
- Blood
- Serum / Plasma
- Urine

Instruments for low to high throughput

- QIAsymphony
- QIAcube Connect
- QIAxcel Connect
- EZ2 Connect
- TissueLyzer

Any analyte

- Genomic DNA
- Plasmid DNA
- Free-circulating DNA
- mRNA/ rRNA/ miRNA
- Proteins
- Circulating tumor cells (CTCs)

2023 menu expansion plans

QIAwave

Expand reduced plastic portfolio launched in 2022

PowerSoil Pro

Additional kits for microbiome portfolio

Ongoing automation upgrade program

QIAcube Connect

Upgrade launched 2021

>14,000 cumulative placements(1)

EZ2 Connect

Upgrades launched 2022

>5,000 cumulative placements (1)



QIAxcel Connect

Upgrade launched 2022

>4,200 cumulative placements (1)

QIAsymphony

Upgrade in development

>3,200 cumulative placements (1)

(1) Cumulative placements as of December 31, 2022

QuantiFERON: Expanding leadership of the gold-standard TB test

Over 100 million patients tested with QuantiFERON

Why we win

Leading portfolio for detection of latent TB

Modern gold standard for TB
QFT-TB Gold Plus
(4th generation test)

Automation partners
DiaSorin
Hamilton, Tecan

Embedded in broad menu
QFT-Lyme
QFT-Monitor
QFT-CMV

2023 menu expansion

QuantiFERON Lyme Disease test
(DiaSorin partnership)
2021: CE-IVD launch
2023: FDA approval anticipated



Lyme disease in western Europe

~230,000
annual cases(1)

~12-14 million
annual tests

~$400-600 m Global Lyme Disease testing market

Increasing volumes for latent TB testing

- Healthcare worker screening
- Back-to-school testing
- Senior living center testing
- National immigration programs
- Prison screening

Latent TB testing market

~70-80 million
annual tests

QIAGEN
~70-80%
share IGRA tests

~25-30% of TB testing market already converted from skin test

Annual TB test volumes



IGRA - Interferon-Gamma Release Assay
1) Comparison of Lyme Disease in the United States and Europe; Adriana R. Marques, Franc Strle, Gary P. Wormser; Emerg Infect Dis. 2021 Aug; 27(8): 2017–2024.

QIAstat-Dx: Capturing share amid syndromic testing demand growth

Why we win

Unrivaled ease-of-use

1 Transfer sample to cartridge

2 Press Run and scan sample

3 Scan barcode of cartridge

4 Insert cartridge

5 View results in 1 hour

More than a “yes/no” answer for deeper clinical insights

QIAstat-Dx
(Low to mid-throughput)

QIAstat-Dx Rise
(High-throughput)

QIAstat-Dx test menu	CE-IVD	FDA
Gastrointestinal	✓✓	✓
Respiratory SARS CoV-2	✓✓	✓✓
Respiratory 4plex	✓✓	
Meningitis	✓✓	**2023**
MPX Viral Vesicular Panel	RUO	RUO **2023**
Anti-Microbial Resistance		
Complicated urinary tract infection	2024	2024
Blood Culture Identification	RUO	RUO **2023**
Pneumonia	2025	2025

Submitted ✓ Completed ✓✓ Planned submission year

(1) Cumulative placements as of December 31, 2022

RUO - Research Use Only

NeuMoDx: Driving new generation of integrated clinical PCR testing

Why we win

Offering the ease of clinical chemistry for molecular testing

Easier
Simple three-step workflow process

Faster
First results in ~1 hour vs. up to 4 hours for others

More versatile
Laboratory-developed test capabilities with full random access

(1) Cumulative placements as of December 31, 2022

LDT - Laboratory Developed Tests

NeuMoDx test menu		CE-IVD	U.S.
Blood-borne viruses	HBV	✓✓	2025
	HCV	✓✓	2025
	HIV	✓✓	2025
Transplant	CMV	✓✓	**2023**
	EBV 2.0	✓✓	**2023**
	BKV	✓✓	
	HSV 1/2	✓✓	
	Adenovirus	✓✓	
	HHV6	✓✓	
Sexual / Reproductive health	CT/NG	✓✓	**2023**
	GBS	✓✓	2024
	TV/MG	✓✓	2025
	HPV	✓✓	
Respiratory diseases	GAS	✓✓	
	SARS-CoV-2	✓✓	(EUA ✓✓) **510k 2023**
	SARS-CoV-2 + Flu A /B +RSV	✓✓	(EUA ✓✓) **510k 2023**
	MPX Viral Vesicular	RUO	RUO

Submitted ✓ Completed ✓✓ Planned submission year

QIAcuity: Enabling wide access to valuable digital PCR insights

Why we win

Integrated instrument offering sample in, result out ease

Scalable
Greater flexibility

Easier
Fully automated workflow

Faster
Over twice as fast time-to-result



Well-positioned to capture an expanding digital PCR market opportunity

>1,300 cumulative placements (1)

QIAcuity One | QIAcuity Four | QIAcuity Eight

Addressing a growing range of applications

- Biopharma
  - Cell and Gene Therapy (CGT) dPCR Assays
  - Residual DNA Quantification Kits
- Proteomics
- Cancer research
- Wastewater testing
- Microbial Detection

2023 menu expansion

- Cell and gene therapy portfolio: MicroSART® bioburden assay
- Protein quantification service

(1) Cumulative placements as of December 31, 2022

Core portfolios: Leading expertise creating a solid foundation of growth potential

Human Identification / Forensics

- Leader in providing sample collection and preparation solution for casework
- Verogen acquisition provides access to complete NGS workflow

VERogen NEW

Every 10 seconds: A crime sample is processed with QIAGEN solutions



Precision Medicine

- >30 master collaboration agreements with pharma companies for companion diagnostics
- Helix partnership expands CDx access to hereditary diseases

Helix NEW

First to offer full range of molecular technologies for CDx programs: PCR, dPCR and NGS



NGS solutions for use with any sequencer

Universal NGS consumables

Best-in-class NGS panels for use with any sequencer

illumina · ion torrent by Thermo Fisher Scientific · Element Biosciences · PacBio · SINGULAR GENOMICS

>4 million samples processed to date using QIAseq NGS panels



QIAGEN Digital Insights

Leader in bioinformatics for research and clinical applications for all NGS workflows

>3 million samples processed to date using QIAGEN Clinical Insights bioinformatics

Capital allocation: Strong balance sheet to create greater value

Disciplined capital allocation strategy

Investing in growth

Expanding test menus and manufacturing capacity, especially in the five pillars

Enhance value with M&A

Ongoing disciplined approach with bolt-on acquisitions

Share repurchase programs

Authorizations from shareholders for various types of repurchase programs

Healthy cash flow and leverage ratio trends



Capital allocation: Enhancing value through bolt-on acquisitions

Expands QIAGEN offering of enzymes and molecular reagents

- Private Polish business acquired in 2022 for ~$60 million
- Recombinant enzymes essential for many lab applications
- Adds new R&D and manufacturing capabilities
- Strengthens Sample technologies portfolio

Strengthening OEM third-party offering while safeguarding QIAGEN supply chains

Strengthens leading position in Human ID / Forensics

- Private U.S. business acquired in January 2023 for ~$150 million
- Adds NGS workflow used to help resolve criminal and missing-persons cases
- Fastest-growing segment of HID market
- Exclusive distribution rights for Illumina MiSeq FGx sequencer

QIAGEN building on position as a top 3 provider of Human ID / Forensics solutions

Summary

Compelling investment case

Focused portfolio with recurring revenues, balanced customer base and geographic diversity

Delivering on our commitments

Beating outlook for 12 quarters with 7 quarters of double-digit CER non-COVID growth

On track for a solid performance in 2023

Confident in maintaining track record of double-digit non-COVID sales growth

Disciplined capital deployment

Focus on bolt-on M&A and increasing shareholder returns with strong cash flow

Thank You